TRENTON, NJ – July 2, 2018 – The American Cancer Society Cancer Action Network’s (ACS CAN) Managing Director of Government Relations Bill Sherman has released the following statement following passage and enactment of the FY 19 budget by the state legislature and Governor Murphy:
Hard to imagine, but only a decade ago we had smoking sections and ashtrays on tables in restaurants. Children could not enjoy a meal with their families without breathing in secondhand smoke.
Today a federal judge ruled the Department of Health and Human Services (HHS) failed to adequately consider how Kentucky’s proposed Medicaid work rules would effect residents’ access to health care as required under federal law.
Cancer survivors, health care providers and representatives from advocacy groups joined Gov. Jeff Colyer today at a signing ceremony for a bill to improve patient quality of life.
AUGUSTA – Nearly one year ago, Maine became the fourth state in the nation to raise the tobacco sales age from 18 to 21.
Nashville, TN — June 28, 2018 — Emily Ogden, who has had a long and successful career around the state legislature, joined the American Cancer Society Cancer Action Network (ACS CAN) this month as the Tennessee government relations director.
The Senate Appropriations Committee approved its FY 2019 Labor, Health and Human Services spending bill today. The bill includes a $2 billion funding increase for the National Institutes of Health (NIH) and a $190 million funding boost for the National Cancer Institute (NCI).
Washington, D.C. – Today the World Trade Organization (WTO) ruled that an Australian law requiring plain packaging of tobacco products does not violate international trade rules.
Washington, D.C. – Today the House Energy and Commerce Subcommittee on Health is scheduled to markup the Palliative Care and Hospice Education and Training Act (PCHETA).
The Centers for Medicare and Medicaid Services (CMS) announced today that they will not approve Massachusetts’ request to restrict Medicaid prescription drug coverage to as few as one drug per class—a practice commonly called a “closed formulary”—unless a state foregoes all manufacturer rebates.